Akebia Therap 
Welcome,         Profile    Billing    Logout  
 3 Products   197 Diseases  3 Products   8 Trials   1008 News 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
perifosine (D21266) / COSCIENS Biopharma
NCT02238496: Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

Completed
1
10
US
Cytoreductive surgery, Resection, Perifosine, AEZS-104/D-21266, KRX-0401, Temsirolimus, Torisel
Andrew B Lassman, MD, Pfizer, AEterna Zentaris
Brain Tumor, Recurrent, Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma
10/17
02/21
Vafseo (vadadustat) / Akebia Therap
NCT04707768: Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Completed
3
456
US
Vadadustat, Mircera®
Akebia Therapeutics
Anemia Associated With Chronic Kidney Disease (CKD)
01/23
01/23
VOICE, NCT06520826: Vafseo Outcomes In-Center Experience

Recruiting
3
2200
US
Vadadustat, Vafseo, Erythropoiesis Stimulating Agent, Epoetin alfa (EPOGEN), Methoxy polyethylene glycol-epoetin beta (Mircera), or Darbepoetin alfa (Aranesp)
USRC Kidney Research, Akebia Therapeutics
Anemia of Chronic Kidney Disease
06/26
06/26
NCT06901505: To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

Not yet recruiting
3
500
NA
Erythropoiesis-Stimulating Agent (ESA), Vadadustat, Vafseo, AKB-6548
Akebia Therapeutics
Anemia of Chronic Kidney Disease
04/26
04/26
NCT04478071: Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)

Completed
2
448
US
vadadustat, AKB-6548, placebo
The University of Texas Health Science Center, Houston, Akebia Therapeutics Inc., United States Department of Defense
Acute Respiratory Distress Syndrome, Coronavirus Infection
03/22
03/22
Auryxia (ferric citrate) / Akebia Therap
NCT03055598: Ferric Citrate in ESRD Pilot Project

Active, not recruiting
4
30
US
Ferric Citrate, Auryxia
Sreedhar Mandayam, Keryx Biopharmaceuticals
End Stage Renal Disease, Chronic Kidney Diseases
09/19
02/20
NCT04485039: Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

Completed
4
44
US
Tecovirimat, TPOXX, sevelamer carbonate oral tablet, Renvela, sucroferric oxyhydroxide chewable tablet, Velphoro, calcium acetate oral tablet, PhosLo, Lanthanum Carbonate Chewable Tablet, Fosrenol
SIGA Technologies, Biomedical Advanced Research and Development Authority, PPD DEVELOPMENT, LP
Smallpox
12/22
04/23
ChiCTR2400083534: Efficacy and Safety of Ferric Citrate in Chinese Hyperphosphatemia Patients Receiving Maintenance Hemodialysis: a Multicenter, Randomized, Open-label, Active-controlled Trial

Completed
3
239
 
Taking ferric citrate tablets according to clinical trial protocols.; Taking comparison tablets according to clinical trial protocols.
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.; Sinomune Pharmaceutical Co., Ltd, Sponsor
Hyperphosphatemia in hemodialysis patients with chronic kidney disease (CKD)
 
 
NCT04543812: PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD

Completed
3
141
RoW
Ferric citrate, Placebo
Panion & BF Biotech Inc.
Anemia of Chronic Kidney Disease
10/22
12/22
FRONTIER, NCT05085275: Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease

Completed
3
289
US
Ferric Citrate 1 GM Oral Tablet [AURYXIA], Auryxia, Placebo
USRC Kidney Research, Akebia Therapeutics
Anemia, Iron Deficiency, Hyperphosphatemia, Renal Insufficiency, Chronic, Renal Anemia, Disease Progression, Cardiovascular, Iron
01/24
01/24
NCT04523727: Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

Recruiting
3
45
US
ferric citrate, KRX-0502
Keryx Biopharmaceuticals
Hyperphosphatemia Related to Chronic Kidney Disease
12/25
10/26
NCT04649411: Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease

Not yet recruiting
3
36
NA
ferric citrate, KRX-0502, standard of care
Keryx Biopharmaceuticals
Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease
01/27
03/27
FIT4KID, NCT04741646: Ferric Citrate and Chronic Kidney Disease in Children

Recruiting
2
160
Canada, US
Ferric Citrate, Auryxia, Placebo
University of California, Los Angeles, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Kidney Diseases
10/27
10/27
KKKR-Nephoxil OS-01, NCT06206135: Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule

Recruiting
N/A
100
RoW
the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)
Kyowa Kirin Korea Co., Ltd.
Hyperphosphatemia
12/25
12/25
NCT06186934: Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients

Recruiting
N/A
600
RoW
the standard-dose group (4 g/day)
Kyowa Kirin Korea Co., Ltd.
Hyperphosphatemia
01/26
01/26
AKB-6899 / Akebia Therap
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
perifosine (D21266) / COSCIENS Biopharma
NCT02238496: Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

Completed
1
10
US
Cytoreductive surgery, Resection, Perifosine, AEZS-104/D-21266, KRX-0401, Temsirolimus, Torisel
Andrew B Lassman, MD, Pfizer, AEterna Zentaris
Brain Tumor, Recurrent, Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma
10/17
02/21
Vafseo (vadadustat) / Akebia Therap
NCT04707768: Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Completed
3
456
US
Vadadustat, Mircera®
Akebia Therapeutics
Anemia Associated With Chronic Kidney Disease (CKD)
01/23
01/23
VOICE, NCT06520826: Vafseo Outcomes In-Center Experience

Recruiting
3
2200
US
Vadadustat, Vafseo, Erythropoiesis Stimulating Agent, Epoetin alfa (EPOGEN), Methoxy polyethylene glycol-epoetin beta (Mircera), or Darbepoetin alfa (Aranesp)
USRC Kidney Research, Akebia Therapeutics
Anemia of Chronic Kidney Disease
06/26
06/26
NCT06901505: To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

Not yet recruiting
3
500
NA
Erythropoiesis-Stimulating Agent (ESA), Vadadustat, Vafseo, AKB-6548
Akebia Therapeutics
Anemia of Chronic Kidney Disease
04/26
04/26
NCT04478071: Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)

Completed
2
448
US
vadadustat, AKB-6548, placebo
The University of Texas Health Science Center, Houston, Akebia Therapeutics Inc., United States Department of Defense
Acute Respiratory Distress Syndrome, Coronavirus Infection
03/22
03/22
Auryxia (ferric citrate) / Akebia Therap
NCT03055598: Ferric Citrate in ESRD Pilot Project

Active, not recruiting
4
30
US
Ferric Citrate, Auryxia
Sreedhar Mandayam, Keryx Biopharmaceuticals
End Stage Renal Disease, Chronic Kidney Diseases
09/19
02/20
NCT04485039: Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

Completed
4
44
US
Tecovirimat, TPOXX, sevelamer carbonate oral tablet, Renvela, sucroferric oxyhydroxide chewable tablet, Velphoro, calcium acetate oral tablet, PhosLo, Lanthanum Carbonate Chewable Tablet, Fosrenol
SIGA Technologies, Biomedical Advanced Research and Development Authority, PPD DEVELOPMENT, LP
Smallpox
12/22
04/23
ChiCTR2400083534: Efficacy and Safety of Ferric Citrate in Chinese Hyperphosphatemia Patients Receiving Maintenance Hemodialysis: a Multicenter, Randomized, Open-label, Active-controlled Trial

Completed
3
239
 
Taking ferric citrate tablets according to clinical trial protocols.; Taking comparison tablets according to clinical trial protocols.
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.; Sinomune Pharmaceutical Co., Ltd, Sponsor
Hyperphosphatemia in hemodialysis patients with chronic kidney disease (CKD)
 
 
NCT04543812: PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD

Completed
3
141
RoW
Ferric citrate, Placebo
Panion & BF Biotech Inc.
Anemia of Chronic Kidney Disease
10/22
12/22
FRONTIER, NCT05085275: Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease

Completed
3
289
US
Ferric Citrate 1 GM Oral Tablet [AURYXIA], Auryxia, Placebo
USRC Kidney Research, Akebia Therapeutics
Anemia, Iron Deficiency, Hyperphosphatemia, Renal Insufficiency, Chronic, Renal Anemia, Disease Progression, Cardiovascular, Iron
01/24
01/24
NCT04523727: Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

Recruiting
3
45
US
ferric citrate, KRX-0502
Keryx Biopharmaceuticals
Hyperphosphatemia Related to Chronic Kidney Disease
12/25
10/26
NCT04649411: Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease

Not yet recruiting
3
36
NA
ferric citrate, KRX-0502, standard of care
Keryx Biopharmaceuticals
Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease
01/27
03/27
FIT4KID, NCT04741646: Ferric Citrate and Chronic Kidney Disease in Children

Recruiting
2
160
Canada, US
Ferric Citrate, Auryxia, Placebo
University of California, Los Angeles, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Kidney Diseases
10/27
10/27
KKKR-Nephoxil OS-01, NCT06206135: Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule

Recruiting
N/A
100
RoW
the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)
Kyowa Kirin Korea Co., Ltd.
Hyperphosphatemia
12/25
12/25
NCT06186934: Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients

Recruiting
N/A
600
RoW
the standard-dose group (4 g/day)
Kyowa Kirin Korea Co., Ltd.
Hyperphosphatemia
01/26
01/26
AKB-6899 / Akebia Therap
No trials found

Download Options